Cargando…

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer

Metastatic colorectal cancer is the fourth most common cause of death due to cancer after those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting therapy seem to be good candidates for curing metastatic colorectal cancer. Two available anti epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yazdi, Mohammad Hossein, Faramarzi, Mohammad Ali, Nikfar, Shekoufeh, Abdollahi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Avicenna Research Institute 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629455/ https://www.ncbi.nlm.nih.gov/pubmed/26605007

Ejemplares similares

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Potential Vaccines for Treating Crohn's Disease
por: Rostami-Nejad, Mohammad, et al.
Publicado: (2020)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis
por: Nikfar, Shekoufeh, et al.
Publicado: (2012)

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution
por: SONODA, HIROMICHI, et al.
Publicado: (2013)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions
por: Abdollahias, Akbar, et al.
Publicado: (2011)

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
por: Rezaie, Ali, et al.
Publicado: (2010)

Are probiotics effective in management of irritable bowel syndrome?
por: Hosseini, Asieh, et al.
Publicado: (2012)

Current opinion on treatment of inflammatory bowel disease in pregnant women
por: Salari, Pooneh, et al.
Publicado: (2012)

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients
por: Mozaffari, Shilan, et al.
Publicado: (2014)

Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter
por: Mousavi, Taraneh, et al.
Publicado: (2021)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
por: Jiang, Zheng, et al.
Publicado: (2013)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
por: Ramadori, G., et al.
Publicado: (2010)

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer
por: Szemitko, Marcin, et al.
Publicado: (2023)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis
por: Zaboli, Pardis, et al.
Publicado: (2017)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease
por: Ehteshami-Afshar, Solmaz, et al.
Publicado: (2011)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
por: Sadeghi, Hosna Mohammad, et al.
Publicado: (2022)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Acknowledgement of manuscript reviewers 2014
por: Abdollahi, Mohammad, et al.
Publicado: (2015)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries
por: Soleymani, Fatemeh, et al.
Publicado: (2018)

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
por: Mohammad Sadeghi, Hosna, et al.
Publicado: (2021)

Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
por: Lakomy, Radek, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fi7q55mhvp8tnckcoc8ndu2dm5